Otros idiomas TRACON Pharmaceuticals, Inc.

Acciones

TCON

US89237H3084

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 02/05/2024			Varia. Cinco días.	Varia. 1 de enero.
1,81 ^USD	+5,85 %		+1,12 %	-48,32 %

03/04	TRACON Pharmaceuticals proporciona información actualizada sobre el ensayo pivotal de fase 2 ENVASARC en curso tras la recomendación del Comité Independiente de Monitorización de Datos de continuar el ensayo según lo previsto	CI
06/03	TRACON PHARMACEUTICALS, INC. : HC Wainwright mantiene su recomendación de compra	ZM

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

TRACON Pharmaceuticals Announces Reverse Stock Split	08/04
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned	03/04
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned	03/04
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
Tracon: Q4 Earnings Snapshot	05/03
Earnings Flash (TCON) TRACON PHARMACEUTICALS Reports Q4 Revenue $3M, vs. Street Est of $1.5M	05/03
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update	05/03
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	05/03
TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024	28/02
TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial	20/12
TRACON Pharmaceuticals, Inc. Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial	20/12
Tracon Licenses Product Development Platform for $3 Million Upfront Payment; Shares Jump	20/11
TRACON Pharmaceuticals, Inc. Announces License of Product Development Platform for $3.0 Million Upfront Payment	20/11
TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment	20/11
Wall Street Set to Open Slightly Higher as Investors Parse Powell Remarks	10/11
Exchange-Traded Funds, Equity Futures Rise After Fed Chief's Comments	10/11
Investors Parse Powell Remarks as US Futures Advance Slightly in Friday Trading	10/11
Top Premarket Gainers	10/11
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Tracon: Q3 Earnings Snapshot	09/11

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas TRACON Pharmaceuticals, Inc.

Acciones

TCON

US89237H3084

Otros idiomas

Filtros